Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Grindeks Group closes 2021 with record high turnover of EUR 231.1 million

This image opens in the lightbox

News provided by

Grindeks

07 Feb, 2022, 09:00 GMT

Share this article

Share toX

Share this article

Share toX

RIGA, Latvia, Feb. 7, 2022 /PRNewswire/ -- The consolidated, provisional financial data of Grindeks Group indicate that the Group has closed 2021 with a record high turnover and profit. In this period, the turnover of Grindeks amounted to EUR 231.1 million, which is EUR 44.0 million or 24% more than in 2020. In 2021, the Group's profit was EUR 41.0 million, which is EUR 22.1 million or 2 times more than in 2020.   

Continue Reading
This image opens in the lightbox
Grindeks Group's results 2021

In 2021, the largest sales volume was accounted for by cardiovascular and central nervous system medicines. Sales growth was also strong in the hospital segment medicine, provided by the subsidiary of Grindeks –  Kalceks company.

In 2021 the products of the Group were exported to 103 countries for the total amount of 218.7 million euros.

Dr. chem. Juris Hmelnickis, Chairman of the Board of Grindeks: "2021 has been a year of change for Grindeks Group, showing that an excellent team can achieve great things. Expanding the range of medicines, understanding patient needs, exploring new markets, taking the course of green thinking and many more important initiatives are the unstoppable driving force for growth. Over the past year, I have seen that challenges can be overcome through constant transformation, where every team member is aware of his or her important role in achieving common ideas and goals. The turnover of EUR 231.1 million is the highest ever for Grindeks, and I would like to thank the team - all the professionals - for the achievements, as well as our partners, healthcare professionals and patients for their continued trust in us!"

The Group sales of finished pharmaceutical products in 2021 totalled EUR 219.5 million, which is an increase of EUR 45.9 million or 26% compared to 2020.

Sales of final dosage forms in the EU and other countries reached EUR 117.5 million in 2021, an increase of EUR 31.6 million or 37% compared to 2020. Compared to 2020, the sales in 2021 increased 29 times in Portugal, 18 times in Brazil, 9 times in the Netherlands, 4 times in the United Arab Emirates and Bulgaria, 3 times in Poland and Norway, and 2 times in Australia and the Czech Republic.

Sales in Russia, other CIS countries and Georgia in 2021 amounted to EUR 102.0 million, which is an increase of EUR 14.3 million or 16% compared to 2020. Compared to 2020, sales in 2021 increased by 57% in Ukraine, 40% in Belarus, 34% in Georgia, 33% in Moldova, 23% in Azerbaijan and Uzbekistan.

The product portfolio of Grindeks includes advanced cardiovascular, central nervous system, oncology and diabetes medicines, while its subsidiary Kalceks offers medicines for the hospital segment. There are currently 64 new JSC Grindeks and 42 new JSC Kalceks medicines in development. In 2021 the registration procedure of 10 new Grindeks generic products was started.

Kalceks has also started decentralized registration procedure of 9 new generic products in EU countries, including first 4 antibiotic product registration for hospital segment.  Due to the company's long experience in the development, manufacture and registration of forms of sterile products, the development of the first ophthalmological products has been launched.

The production of active pharmaceutical ingredients is also very important for Grindeks and is one of the Group's competitive advantages. The company currently produces 25 active pharmaceutical ingredients. This segment increases its independence from raw material producers, which is why the company is developing 36 new active pharmaceutical ingredients. Most of export of active pharmaceutical ingredients produced by Grindeks are made to the European Union, Japan, the USA and Australia.

In 2021, Kalceks achieved outstanding results. Sales grew rapidly, increasing both the number of export countries and the number of products with 7 new generic products. Product portfolio in 2021 contained 35 medicines. Kalceks products generated sales of EUR 66.7 million in 2021, which is an increase of EUR 26.0 million or 64% compared to 2020. Kalceks products were exported to 77 countries in 2021, the main ones being the Netherlands, Mexico, the UK, the Czech Republic and Poland. 

Kirovs Lipmans, Chairman of the Council of Grindeks: "Despite various obstacles posed by the pandemic, last year Grindeks focused on its priorities - new products and global expansion. I am truly pleased with the achievements of the Grindeks Group in 2021. The excellent results - turnover of EUR 231.1 million and profit of EUR 41 million - clearly demonstrate competitiveness of Grindeks in the global arena. This is the basis for successful development projects."

In 2021, Grindeks paid special attention to improving production infrastructure and installing new production facilities, including the current modernisation of the final dosage form laboratory.

In order to continue the gradual and steady growth of the Group in the long term, the Grindeks Innovation Centre will be built in Riga, Asotes street 12, in several stages. In 2021, a design contract was signed and site improvement works were carried out. The Innovation Centre will provide complicated production processes for active pharmaceutical ingredients, state-of-the-art technological equipment, as well as automated and energy-efficient solutions. It will be the largest pharmaceutical innovation centre in the Baltic region.

About Grindeks Group

Grindeks is an international pharmaceutical group, and its main activities are research, development, production and sale of original products, generic medicines and active pharmaceutical ingredients.

Grindeks Group consists of JSC Grindeks and its companies: JSC Kalceks in Latvia, JSC Tallinn Pharmaceutical Plant in Estonia, HBM Pharma s.r.o. in Slovakia, LLC Grindeks Rus in Russia and LLC Namu Apsaimniekosanas projekti in Latvia. Representation offices have been opened in 10 countries.

The main therapeutic groups of Grindeks are cardiovascular, central nervous system, anti-cancer and diabetes drugs. Kalceks specializes in medicines for the hospital segment.

The product range consists of the original products Mildronate® (meldonium) and Ftorafur® (tegafur), generic medicines as well as active pharmaceutical ingredients.

In 2021 the Group exported its products to 103 countries. Major markets for Grindeks are the European Union countries,  Russian and other CIS countries, Australia, United Arab Emirates and Israel.

Infographic of results: https://infogram.com/grindeks-group-has-reached-record-high-turnover-and-profit-in-2021-1hzj4o3vx9z534p?live
Video: https://www.youtube.com/watch?v=ungCtl5tctU
Photos: https://grindeks.eu/company/about-grindeks/photos/

Logo - https://mma.prnewswire.com/media/1508714/Grindex_Logo.jpg

Modal title

Also from this source

Baltics leading pharmaceutical company Grindeks expands to new export markets worldwide

Baltics leading pharmaceutical company Grindeks expands to new export markets worldwide

The leading pharmaceutical company in the Baltics, Grindeks, continues to strengthen its global presence by entering new export markets. This year,...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Pharmaceuticals

Pharmaceuticals

Medical Pharmaceuticals

Medical Pharmaceuticals

Earnings

Earnings

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.